Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
melanoma (14) 14
oncology (11) 11
index medicus (9) 9
ipilimumab (8) 8
humans (7) 7
adult (6) 6
aged (6) 6
immunology (6) 6
middle aged (6) 6
cancer (5) 5
female (5) 5
male (5) 5
metastasis (5) 5
overall survival (5) 5
survival (5) 5
association (4) 4
best overall response (4) 4
care and treatment (4) 4
ctla-4 variants (4) 4
genetic aspects (4) 4
melanoma - metabolism (4) 4
metastatic melanoma (4) 4
predictive/prognostic factor (4) 4
young adult (4) 4
adverse events (3) 3
aged, 80 and over (3) 3
cancer patients (3) 3
cancer therapies (3) 3
chemotherapy (3) 3
endothelial growth-factor (3) 3
health aspects (3) 3
immunotherapy (3) 3
italy (3) 3
melanoma - drug therapy (3) 3
melanoma - genetics (3) 3
mutation (3) 3
neoplasms. tumors. oncology. including cancer and carcinogens (3) 3
patients (3) 3
predictive (3) 3
prognosis (3) 3
research paper (3) 3
therapy (3) 3
tumors (3) 3
usage (3) 3
analysis (2) 2
antineoplastic agents - therapeutic use (2) 2
apoptosis (2) 2
bevacizumab (2) 2
biomarkers (2) 2
cell biology (2) 2
cell line, tumor (2) 2
cell receptors (2) 2
circulating tumor cells (2) 2
ctla-4 protein (2) 2
cutaneous melanoma (2) 2
dabrafenib (2) 2
drug resistance, neoplasm (2) 2
drug therapy (2) 2
elderly-patients (2) 2
health care sciences & services (2) 2
invasion (2) 2
invasiveness (2) 2
kaplan-meier estimate (2) 2
medicine & public health (2) 2
melanoma - mortality (2) 2
melanoma - pathology (2) 2
melanoma molecular biomarker (2) 2
melanoma relapse (2) 2
metastases (2) 2
neoplasm metastasis (2) 2
neoplasms (2) 2
neoplasms - drug therapy (2) 2
nursing (2) 2
nursing management/nursing research (2) 2
pain medicine (2) 2
pax3 (2) 2
pembrolizumab (2) 2
prognostic factor (2) 2
proliferation (2) 2
proto-oncogene proteins b-raf - genetics (2) 2
proto-oncogene proteins b-raf - metabolism (2) 2
psychological distress (2) 2
qrt-pcr (2) 2
rehabilitation (2) 2
rehabilitation medicine (2) 2
research (2) 2
skin neoplasms - mortality (2) 2
solid tumors (2) 2
time factors (2) 2
treatment outcome (2) 2
vascular endothelial growth factor (2) 2
5-fluorouracil toxicity (1) 1
abridged index medicus (1) 1
acquired resistance (1) 1
activation (1) 1
adaptor proteins, signal transducing - metabolism (1) 1
adenosine triphosphatases - metabolism (1) 1
adipose-tissue (1) 1
advanced melanoma (1) 1
agent (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) is a novel marker for patients with BRAF-mutated metastatic melanoma
by Audrito, Valentina and Managò, Antonella and Zamporlini, Federica and Rulli, Eliana and Gaudino, Federica and Madonna, Gabriele and D'Atri, Stefania and Cappellini, Gian Carlo Antonini and Ascierto, Paolo Antonio and Massi, Daniela and Raffaelli, Nadia and Mandalà, Mario and Deaglio, Silvia
Oncotarget, ISSN 1949-2553, 04/2018, Volume 9, Issue 27, pp. 18997 - 19005
Metastatic melanoma carrying BRAF mutations represent a still unmet medical need as success of BRAF inhibitors is limited by development of resistance.... 
Tumor marker | Metastatic melanoma | Prognosis | Resistance to therapy | NAMPT
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Abstract 474: Alterations of micro-RNAs are associated with melanoma resistance to BRAF inhibitors: Role of miR-126
by Caporali, Simona and Levati, Lauretta and Alvino, Ester and Amaro, Adriana and Lacal, Pedro Miguel and Bonmassar, Laura and Bassi, Cristian and Lupini, Laura and Cappellini, Gian Carlo Antonini and Pfeffer, Ulrich and Negrini, Massimo and Felli, Nadia and Carè, Alessandra and Russo, Giandomenico and D'Atri, Stefania
Cancer Research, ISSN 0008-5472, 07/2018, Volume 78, Issue 13 Supplement, pp. 474 - 474
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
by Ferrucci, Pier Francesco and Gandini, Sara and Cocorocchio, Emilia and Pala, Laura and Baldini, Federica and Mosconi, Massimo and Cappellini, Gian Carlo Antonini and Albertazzi, Elena and Martinoli, Chiara
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 45, pp. 79809 - 79815
As diverse therapeutic options are now available for advanced melanoma patients, predictive markers that may assist treatment decision are needed. A model... 
Biomarker | Ipilimumab | Eosinophil | Melanoma | Predictive | SURVIVAL | TRIAL | METASTATIC MELANOMA | PEMBROLIZUMAB | ipilimumab | predictive | melanoma | TO-LYMPHOCYTE RATIO | eosinophil | biomarker | CELL BIOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Predictors of mood disorders in cancer patients’ caregivers
by Mazzotti, Eva and Mazzotti, Eva and Sebastiani, Claudia and Sebastiani, Claudia and Antonini Cappellini, Gian Carlo and Antonini Cappellini, Gian Carlo and Marchetti, Paolo and Marchetti, Paolo
Supportive Care in Cancer, ISSN 0941-4355, 2/2013, Volume 21, Issue 2, pp. 643 - 647
Patients’ care has been associated with a high burden of psychological symptoms in caregivers. This study identifies characteristics associated with mood... 
Pain Medicine | Nursing | Rehabilitation Medicine | Medicine & Public Health | Coping and adaptation | Psychological distress | Caregiver | Mood disorders | Oncology | Families’ burden | Nursing Management/Nursing Research | Cancer | Families' burden | DEPRESSION SCALE | HOSPITAL ANXIETY | PARTNERS | ONCOLOGY | FAMILIES | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | PSYCHOLOGICAL IMPACT | COPING STRATEGIES | Caregivers - statistics & numerical data | Caregivers - psychology | Humans | Middle Aged | Risk Factors | Male | Stress, Psychological - psychology | Forecasting | Neoplasms | Mood Disorders - epidemiology | Mood Disorders - etiology | Young Adult | Mood Disorders - diagnosis | Stress, Psychological - epidemiology | Adult | Female | Italy | Aged | Stress, Psychological - complications | Caregivers | Family | Cancer patients | Care and treatment | Stress (Psychology) | Depression, Mental | Families & family life | Emotional disorders
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor
by Caporali, Simona and Alvino, Ester and Lacal, Pedro Miguel and Levati, Lauretta and Giurato, Giorgio and Memoli, Domenico and Caprini, Elisabetta and Cappellini, Gian Carlo Antonini and D'Atri, Stefania
International Journal of Oncology, ISSN 1019-6439, 09/2016, Volume 49, Issue 3, pp. 1164 - 1174
BRAF inhibitors (BRAFi) have proven clinical benefits in patients with BRAF-mutant melanoma. However, acquired resistance eventually arises. The effects of... 
GSK2126458A | Melanoma | Dabrafenib | BRAF | Drug resistance | Invasion | Bevacizumab | MUTANT MELANOMA | melanoma | IMPROVED SURVIVAL | VEMURAFENIB RESISTANCE | RANDOMIZED CONTROLLED-TRIAL | MUTATED MELANOMA | MATRIX METALLOPROTEINASES | METASTATIC MELANOMA | PROMOTES INVASIVENESS | invasion | MEK INHIBITION | ONCOLOGY | bevacizumab | drug resistance | dabrafenib | ENDOTHELIAL GROWTH-FACTOR
Journal Article
Details down arrow
6. Full Text Targeting the PTTG1 oncogene impairs proliferation and invasiveness of melanoma cells sensitive or with acquired resistance to the BRAF inhibitor dabrafenib
by Caporali, Simona and Alvino, Ester and Lacal, Pedro Miguel and Ruffini, Federica and Levati, Lauretta and Bonmassar, Laura and Scoppola, Alessandro and Marchetti, Paolo and Mastroeni, Simona and Cappellini, Gian Carlo Antonini and D'Atri, Stefania
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 69, pp. 113472 - 113493
The pituitary tumor transforming gene 1 (PTTG1) is implicated in tumor growth, metastasis and drug resistance. Here, we investigated the involvement of PTTG1... 
Dabrafenib | Proliferation | PTTG1 | Invasion | Melanoma | CANCER-CELLS | proliferation | SOLID TUMORS | INDUCED APOPTOSIS | melanoma | MALIGNANT-MELANOMA | DEPENDENT KINASE INHIBITOR | MESENCHYMAL TRANSITION | CELL BIOLOGY | invasion | PROMOTES MIGRATION | MUTATED METASTATIC MELANOMA | dabrafenib | TUMOR-TRANSFORMING GENE-1 | ENDOTHELIAL GROWTH-FACTOR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
by Ascierto, Paolo Antonio and Simeone, Ester and Sileni, Vanna Chiarion and Vecchio, Michele Del and Marchetti, Paolo and Cappellini, Gian Carlo Antonini and Ridolfi, Ruggero and de Rosa, Francesco and Cognetti, Francesco and Ferraresi, Virginia and Testori, Alessandro and Queirolo, Paola and Bernengo, Maria Grazia and Guida, Michele and Galli, Luca and Mandalà, Mario and Cimminiello, Carolina and Rinaldi, Gaetana and Carnevale-Schianca, Fabrizio and Maio, Michele
Cancer Investigation, ISSN 0735-7907, 5/2014, Volume 32, Issue 4, pp. 144 - 149
Of 93 patients with pretreated, BRAFV600 mutation-positive advanced melanoma who received vemurafenib or dabrafenib before (n = 45) or after (n = 48) treatment... 
Treatment | Molecular biology | Cutaneous melanoma | Tumor immunology | THERAPY | ONCOLOGY | FOLLOW-UP | VEMURAFENIB | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Middle Aged | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Melanoma - enzymology | Male | Molecular Targeted Therapy | Indoles - administration & dosage | Young Adult | Skin Neoplasms - enzymology | Time Factors | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Retrospective Studies | Proto-Oncogene Proteins B-raf - metabolism | Skin Neoplasms - pathology | Drug Administration Schedule | Kaplan-Meier Estimate | Treatment Outcome | Disease Progression | Melanoma - secondary | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Italy | Aged | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Placenta growth factor and neuropilin-1 collaborate in promoting melanoma aggressiveness
by Pagani, Elena and Ruffini, Federica and Cappellini, Gian Carlo Antonini and Scoppola, Alessandro and Fortes, Cristina and Marchetti, Paolo and Graziani, Grazia and D'Atri, Stefania and Lacal, Pedro Miguel
International Journal of Oncology, ISSN 1019-6439, 04/2016, Volume 48, Issue 4, pp. 1581 - 1589
The placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family, which shares with VEGF-A the tyrosine kinase receptor... 
bevacizumab | melanoma | vasculogenic mimicry | PlGF | neuropilin-1 | SURVIVAL | ACTIVATION | VEGF | INHIBITS GROWTH | FACTOR RECEPTOR-1 | INVASIVENESS | AGENT | BREAST-CANCER CELLS | ONCOLOGY | ENDOTHELIAL-CELLS
Journal Article
Details down arrow
9. Full Text miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A
by Caporali, S and Amaro, A and Levati, L and Alvino, E and Lacal, PM and Mastroeni, S and Ruffini, F and Bonmassar, L and Cappellini, GCA and Felli, N and Care, A and Pfeffer, U and D'Atri, S
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, ISSN 1756-9966, 06/2019, Volume 38, Issue 1, pp. 272 - 24
BackgroundDevelopment of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi) remains a great challenge for targeted therapy in patients with BRAF-mutant... 
MIGRATION | SURVIVAL | THERAPEUTICS | MICRORNA-126 | proliferation | CANCER CELLS | BRAF inhibitors | melanoma | miR-126-3p | DRUG-RESISTANCE | acquired resistance | invasiveness | METASTATIC MELANOMA | ONCOLOGY | PATHWAY | BRAF INHIBITOR RESISTANCE | ENDOTHELIAL GROWTH-FACTOR | Cell proliferation | Prognosis | MicroRNA | Gene mutations | Melanoma | Genetic aspects | Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Abstract LB-115: Baseline neutrophil to lymphocyte ratio as a selection criterion for ipilimumab treatment in metastatic melanoma patients
by Ferrucci, Pier Francesco and Gandini, Sara and Battaglia, Angelo and Alfieri, Salvatore and Pala, Laura and Di Giacomo, Annamaria and Amato, Giovanni and Antonini Cappellini, Gian Carlo and Giannarelli, Diana and Cocorocchio, Emilia and Martinoli, Chiara
Cancer Research, ISSN 0008-5472, 08/2015, Volume 75, Issue 15 Supplement, pp. LB-115 - LB-115
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study
by Pistillo, Maria Pia and Fontana, Vincenzo and Morabito, Anna and Dozin, Beatrice and Laurent, Stefania and Carosio, Roberta and Banelli, Barbara and Ferrero, Francesca and Spano, Laura and Tanda, Enrica and Ferrucci, Pier Francesco and Martinoli, Chiara and Cocorocchio, Emilia and Guida, Michele and Tommasi, Stefania and De Galitiis, Federica and Pagani, Elena and Antonini Cappellini, Gian Carlo and Marchetti, Paolo and Quaglino, Pietro and Fava, Paolo and Osella-Abate, Simona and Ascierto, Paolo Antonio and Capone, Mariaelena and Simeone, Ester and Romani, Massimo and Spagnolo, Francesco and Queirolo, Paola and Italian Melanoma Intergrp IMI and Italian Melanoma Intergroup (IMI) and On behalf of the Italian Melanoma Intergroup (IMI)
Cancer Immunology, Immunotherapy, ISSN 0340-7004, 01/2019, Volume 68, Issue 1, pp. 97 - 107
CTLA-4 blockade by means of ipilimumab (IPI) potentiates the immune response and improves overall survival (OS) in a minority of metastatic melanoma (MM)... 
Best response | Adverse events | Overall survival | Ipilimumab | Soluble CTLA-4 | NEUTROPHIL | VARIANTS | LONG-TERM SURVIVAL | POLYMORPHISM | IMMUNOLOGY | LYMPHOCYTE ANTIGEN 4 | REGULATOR | THERAPY | ONCOLOGY | RELEVANCE | ASSOCIATION | EXPRESSION | Melanoma - metabolism | Predictive Value of Tests | Humans | Middle Aged | Kaplan-Meier Estimate | Solubility | CTLA-4 Antigen - metabolism | Male | Melanoma - pathology | Biomarkers, Tumor - blood | Young Adult | Neoplasm Metastasis | Antineoplastic Agents, Immunological - therapeutic use | CTLA-4 Antigen - blood | Ipilimumab - therapeutic use | Melanoma - drug therapy | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Female | Italy | Aged | Serum levels | CTLA-4 protein | Immune response | Melanoma | Biomarkers | Metastasis | Patients | Digestive tract | Enzyme-linked immunosorbent assay | Metastases
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Treatment-related side effects and quality of life in cancer patients
by Mazzotti, Eva and Antonini Cappellini, Gian Carlo and Buconovo, Stefania and Morese, Roberto and Scoppola, Alessandro and Sebastiani, Claudia and Marchetti, Paolo
Supportive Care in Cancer, ISSN 0941-4355, 10/2012, Volume 20, Issue 10, pp. 2553 - 2557
Cancer leads to a complicated pattern of change in quality of life (QoL).The aims of this study were to assess the impact of treatment-related side effects on... 
Pain Medicine | Cancer patients | Rehabilitation Medicine | Nursing | Well-being | Medicine & Public Health | Treatment-related | Oncology | Nursing Management/Nursing Research | Quality of life | RECOGNITION | PSYCHIATRIC MORBIDITY | ANXIETY | SYMPTOM PREVALENCE | CHEMOTHERAPY | BREAST-CANCER | WOMEN | CLUSTERS | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | PSYCHOLOGICAL DISTRESS | REHABILITATION | ASSOCIATION | Humans | Middle Aged | Logistic Models | Male | Antineoplastic Agents - therapeutic use | Neoplasms - drug therapy | Regression Analysis | Antineoplastic Agents - adverse effects | Aged, 80 and over | Quality of Life | Adult | Female | Surveys and Questionnaires | Aged | Care and treatment | Chemotherapy | Analysis | Cancer | Cancer therapies | Side effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
by Cortellini, Alessio and Buti, Sebastiano and Santini, Daniele and Perrone, Fabiana and Giusti, Raffaele and Tiseo, Marcello and Bersanelli, Melissa and Michiara, Maria and Grassadonia, Antonino and Brocco, Davide and Tinari, Nicola and De Tursi, Michele and Zoratto, Federica and Veltri, Enzo and Marconcini, Riccardo and Malorgio, Francesco and Garufi, Carlo and Russano, Marco and Anesi, Cecilia and Zeppola, Tea and Filetti, Marco and Marchetti, Paolo and Botticelli, Andrea and Antonini Cappellini, Gian Carlo and De Galitiis, Federica and Vitale, Maria Giuseppa and Sabbatini, Roberto and Bracarda, Sergio and Berardi, Rossana and Rinaldi, Silvia and Tudini, Marianna and Silva, Rosa Rita and Pireddu, Annagrazia and Atzori, Francesco and Chiari, Rita and Ricciuti, Biagio and Iacono, Daniela and Migliorino, Maria Rita and Rossi, Antonio and Porzio, Giampiero and Cannita, Katia and Ciciarelli, Valeria and Fargnoli, Maria Concetta and Ascierto, Paolo Antonio and Ficorella, Corrado
The Oncologist, ISSN 1083-7159, 06/2019, Volume 24, Issue 6, pp. e327 - e337
Background Patients with a history of autoimmune diseases (AIDs) have not usually been included in clinical trials with immune checkpoint inhibitors. Materials... 
Autoimmune disease | Immune checkpoint inhibitors | Immunotherapy | Performance status | Anti‐programmed death‐1 | Sex | Anti-programmed death-1 | CRITERIA | MANAGEMENT | EFFICACY | IMMUNE-CHECKPOINT INHIBITORS | THERAPY | ONCOLOGY | ADVANCED MELANOMA | SEX-DIFFERENCES | ELDERLY-PATIENTS | ASSOCIATION | ADVERSE EVENTS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text CTLA-4 gene variant -1661A>G may predict the onset of endocrine adverse events in metastatic melanoma patients treated with ipilimumab
by Queirolo, Paola and Dozin, Beatrice and Morabito, Anna and Banelli, Barbara and Carosio, Roberta and Fontana, Vincenzo and Ferrucci, Pier Francesco and Martinoli, Chiara and Cocorocchio, Emilia and Ascierto, Paolo A and Madonna, Gabriele and Simeone, Ester and De Galitiis, Federica and Antonini Cappellini, Gian Carlo and Marchetti, Paolo and Guida, Michele and Tommasi, Stefania and Ghilardi, Laura and Merelli, Barbara and Fava, Paolo and Osella-Abate, Simona and Guidoboni, Massimo and Romani, Massimo and Ferone, Diego and Spagnolo, Francesco and Pistillo, Maria Pia and IMI and Italian Melanoma Intergroup (IMI)
European Journal of Cancer, ISSN 0959-8049, 07/2018, Volume 97, pp. 59 - 61
ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Pharmacogenomics and chemotherapy
by Paris, Ida and Cappellini, Gian Carlo Antonini and Malaguti, Paola and Bassanelli, Maria and Marchetti, Paolo
Recenti progressi in medicina, ISSN 0034-1193, 07/2010, Volume 101, Issue 7-8, p. 277
Genetic factors could alter drug metabolism and activity and could predict drug toxicity and/or efficacy. Several chemotherapy agents are administered in... 
Camptothecin - toxicity | Fluorouracil - toxicity | Drug Resistance, Neoplasm | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - metabolism | Taxoids - therapeutic use | Toxicology | Time Factors | Enzyme Inhibitors - toxicity | Antimetabolites, Antineoplastic - metabolism | Camptothecin - analogs & derivatives | Fluorouracil - metabolism | Camptothecin - metabolism | Pharmacogenetics | Neoplasms - mortality | Genotype | Thymidylate Synthase - genetics | Cisplatin | Neoplasms - drug therapy | Polymorphism, Genetic | Antineoplastic Agents, Phytogenic - toxicity | Antimetabolites, Antineoplastic - therapeutic use | Animals | Antimetabolites, Antineoplastic - toxicity | Survival Analysis | Dihydrouracil Dehydrogenase (NADP)
Journal Article
Details down arrow
16. Full Text Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity
by Minniti, G and Anzellini, D and Reverberi, C and Cappellini, GCA and Marchetti, L and Bianciardi, F and Bozzao, A and Osti, M and Gentile, PC and Esposito, V
JOURNAL FOR IMMUNOTHERAPY OF CANCER, ISSN 2051-1426, 04/2019, Volume 7, Issue 1, pp. 102 - 11
Purpose: To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma... 
SURVIVAL | SOLID TUMORS | OPEN-LABEL | IMMUNOLOGY | fractionated stereotactic radiosurgery | stereotactic radiosurgery | RADIATION-THERAPY | CELL LUNG-CANCER | RESPONSES | PEMBROLIZUMAB | ONCOLOGY | LOCAL RADIATION | immunotherapy | RADIOTHERAPY | OUTCOMES | melanoma brain metastases | checkpoint inhibitors | Usage | Care and treatment | Ipilimumab | Radiosurgery | Dosage and administration | Metastasis | Research | Cancer | Antigens | Toxicity | Brain cancer | Immunotherapy | Melanoma | Radiation therapy | Patients | Cancer therapies | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text High expression of the mismatch repair protein MSH6 is associated with poor patient survival in melanoma
by Alvino, Ester and Passarelli, Francesca and Cannavò, Elda and Fortes, Cristina and Mastroeni, Simona and Caporali, Simona and Jiricny, Josef and Cappellini, Gian Carlo Antonini and Scoppola, Alessandro and Marchetti, Paolo and Modesti, Andrea and D'Atri, Stefania
American Journal of Clinical Pathology, ISSN 0002-9173, 2014, Volume 142, Issue 1, pp. 121 - 132
Objectives: The outcome of patients with primary melanoma (PM) cannot be completely explained based on currently adopted clinical-histopathologic criteria. In... 
MSH6 | Survival | Mismatch repair | Melanoma | APOPTOSIS | MALIGNANT MELANOCYTIC LESIONS | METHYLATING AGENTS | METASTASIS | IMMUNOREACTIVITY | DYSPLASTIC NEVI | PATHOLOGY | G CHECKPOINT | BENIGN | CUTANEOUS MELANOMA | DNA-REPAIR | Melanoma - metabolism | MutL Protein Homolog 1 | Prognosis | Humans | Middle Aged | Adenosine Triphosphatases - metabolism | Male | Nuclear Proteins - metabolism | Survival Rate | MutS Homolog 2 Protein - metabolism | Skin Neoplasms - metabolism | DNA-Binding Proteins - metabolism | Skin Neoplasms - mortality | DNA Mismatch Repair | DNA Repair Enzymes - metabolism | Adult | Female | Aged | Mismatch Repair Endonuclease PMS2 | Adaptor Proteins, Signal Transducing - metabolism | Nevus - metabolism | Melanoma - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Pharmacogenomics and chemotherapy
by Paris, Ida and Cappellini, Gian Carlo Antonini and Malaguti, Paola and Bassanelli, Maria and Marchetti, Paolo
Recenti Progressi in Medicina, ISSN 0034-1193, 2010, Volume 101, Issue 7-8, pp. 277 - 282
Irinotecan toxicity | Taxanes and drug transporters | UGT1A1 | 5-fluorouracil toxicity | Thymidylate synthase gene polymorphisms | MTHFR | Dihydropyrimidine dehydrogenase | ERCC1 expression in non small cell lung cancer
Journal Article
Details down arrow
19. Full Text Association of CTLA-4 gene variants with response to therapy and long-term survival in metastatic melanoma patients treated with ipilimumab: An Italian melanoma intergroup study
by Queirolo, Paola and Dozin, Beatrice and Morabito, Anna and Banelli, Barbara and Piccioli, Patrizia and Fava, Cristiana and Leo, Claudio and Carosio, Roberta and Laurent, Stefania and Fontana, Vincenzo and Ferrucci, Pier Francesco and Martinoli, Chiara and Cocorocchio, Emilia and Battaglia, Angelo and Ascierto, Paolo A and Capone, Mariaelena and Simeone, Ester and De Galitiis, Federica and Pagani, Elena and Cappellini, Gian Carlo Antonini and Marchetti, Paolo and Guida, Michele and Tommasi, Stefania and Mandalà, Mario and Merelli, Barbara and Quaglino, Pietro and Fava, Paolo and Guidoboni, Massimo and Romani, Massimo and Spagnolo, Francesco and Pistillo, Maria Pia and IMI
Frontiers in Immunology, ISSN 1664-3224, 04/2017, Volume 8
Ipilimumab (IPI) blocks CTLA- 4 immune checkpoint resulting in T cell activation and enhanced antitumor immunity. IPI improves overall survival (OS) in 22% of... 
Best overall response | CTLA-4 variants | Overall survival | Ipilimumab | Melanoma | Predictive/prognostic factor | SUSCEPTIBILITY | melanoma | ANTIBODY | IMMUNOLOGY | CANCER | predictive/prognostic factor | BIOMARKERS | POLYMORPHISMS | INHIBITION | AUTOIMMUNITY | ipilimumab | DISEASE | overall survival | BLOCKADE | CYTOTOXICITY | best overall response | Usage | Genetic variation | Physiological aspects | Genetic aspects | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Melanoma cells with acquired resistance to dabrafenib display changes in miRNA expression pattern and respond to this drug with an increase of invasiveness, which is abrogated by inhibition of NF-κB or the PI3K/mTOR signalling pathway
by Caporali, Simona and Alvino, Ester and Amaro, Adriana and Lacal, Pedro Miguel and Levati, Lauretta and Atzori, Maria Grazia and Cappellini, Gian Carlo Antonini and Ruffini, Federica and Bonmassar, Enzo and Pfeffer, Ulrich and D'Atri, Stefania
Journal of Translational Medicine, ISSN 1479-5876, 01/2015, Volume 13, Issue Suppl 1, pp. 1 - 2
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights